Pierre Legault a rejoint Poxel en apportant plus de 35 ans d鈥檈xp茅rience de l鈥檌ndustrie biotechnologique et pharmaceutique. Il est membre du Conseil d鈥橝dministration de Tobira Therapeutics ...
POXEL SA (Euronext - POXEL - FR0012432516), a clinical-stage biopharmaceutical company focused on the development of novel treatments for type 2 diabetes and metabolic disease, today announced that...
RSS